SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Albright, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albright, A. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Intrathecal Baclofen in Cerebral Palsy Movement Disorders

A. Leland Albright, MD

Department of Neurosurgery, Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine, Pittsburgh, PA

Intrathecal baclofen reduces spasticity in individuals with cerebral palsy. Intrathecal doses are far lower than oral doses and the effects are considerably greater, and the side effects are fewer. Response to intrathecal baclofen must be confirmed by a screening trial before implantation of a pump for chronic infusion. Intrathecal baclofen reduces spasticity in the upper and lower extremities and is often associated with improved gait and upper extremity function. Quality of life improves for patients and caregivers. The Medtronic pump has been exceedingly reliable and typically functions for 4 or 5 years. The currently available intrathecal catheter is associated with far fewer complications than the initial catheter. Baclofen overdoses are unusual and are usually caused by pump programming errors rather than pump malfunction. Preliminary studies suggest that continuous intrathecal baclofen infusion reduces generalized dystonia in cerebral palsy. Screening to determine response of dystonia to intrathecal baclofen is by continuous infusion. The doses required to reduce dystonia are higher than those for cerebral spasticity. Additional investigations are underway to quantify the effects of continuous intrathecal baclofen infusion on communication, disability, and dystonia. (J Child Neurol 1996;11(Suppl 1): S29-S35).

Journal of Child Neurology, Vol. 11, No. 1 suppl, S29-S35 (1996)
DOI: 10.1177/088307389601100105
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Child NeurolHome page
R. A. Brumback
The Silver Jubilee: Journal of Child Neurology Turns 25
J Child Neurol, January 1, 2010; 25(1): 4 - 31.
[PDF]

Home page
 J Child NeurolHome page
G. de Lissovoy, L. S. Matza, H. Green, M. Werner, and T. Edgar
Cost-effectiveness of Intrathecal Baclofen Therapy for the Treatment of Severe Spasticity Associated With Cerebral Palsy
J Child Neurol, January 1, 2007; 22(1): 49 - 59.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
J. E. Brunstrom
Clinical Considerations in Cerebral Palsy and Spasticity
J Child Neurol, January 1, 2001; 16(1): 10 - 15.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
F. A. Boop
Evolution of the Neurosurgical Management of Spasticity
J Child Neurol, January 1, 2001; 16(1): 54 - 57.
[PDF]


Advertisement